Cardioprotective Properties of the Platelet P2Y12 Receptor Inhibitor, Cangrelor: Protective in Diabetics and Reliant Upon the Presence of Blood

Two Classes of Anti-Platelet Drugs Reduce Anatomical Infarct Size in Monkey Hearts

(2013) Xi-Ming Yang et al.   CARDIOVASCULAR DRUGS AND THERAPY

Triple Therapy Greatly Increases Myocardial Salvage During Ischemia/Reperfusion in the in situ Rat Heart

(2013) Xi-Ming Yang et al.   CARDIOVASCULAR DRUGS AND THERAPY

Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling

(2013) Hannah J. Whittington et al.   CARDIOVASCULAR RESEARCH

Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties

(2013) Nicola Ferri et al.   DRUGS

Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients

(2013) Guido Parodi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Platelet P2Y12 Blockers Confer Direct Postconditioning-Like Protection in Reperfused Rabbit Hearts

(2012) Xi-Ming Yang et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

The mitochondrial permeability transition pore as a target for preconditioning and postconditioning

(2009) Derek J. Hausenloy et al.   BASIC RESEARCH IN CARDIOLOGY